The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

2025-12-30

The first series of the World Chinese Medicine Forum in 2025—the Advanced Clinical Training Series for Rheumatology by Famous Chinese Medicine Experts—was successfully held from May to June 2025. This series focused on the diagnosis and treatment of rheumatic and autoimmune diseases with Traditional Chinese Medicine (TCM). It consisted of 2 core lectures conducted online, attracting hundreds of TCM practitioners and scholars from around the world.

As an independent, non-profit academic platform, the World Chinese Medicine Forum remains dedicated to tracking the latest developments, cutting-edge trends, and key issues in modern TCM research, promoting academic exchange and professional growth within the industry. Since its establishment in 2022, the Forum has successfully organized six series of academic events, covering multiple TCM specialty areas such as gynecology, pediatrics, gastroenterology, dermatology, pain management, and rheumatology. Participants came from over ten countries and regions worldwide, including the United States, Canada, Australia, the United Kingdom, Brazil, and China, with more than 60% being non-ethnic Chinese, reflecting the Forum’s growing global reach.

This forum was organized by Tianjiang Pharmaceutical and Blue Light Inc., with continued support from multiple TCM associations and institutions across North America.

Highlights of the First Series in 2025

This forum delved deeply into rheumatology, featuring distinguished Chinese rheumatology experts who delivered specialized lectures. The training was held in two sessions: on May 25th, Director Ji Wei systematically shared TCM differentiation approaches and clinical experience in treating rheumatic diseases. On June 15th, Director Su Li provided an in-depth exploration of the comprehensive application and latest advances of TCM in managing rheumatic conditions. Both lectures combined academic depth with clinical practicality, offering valuable learning opportunities for overseas TCM practitioners, acupuncturists, and students.

For detailed information on the first series of lectures in 2025, please visit the official forum website: https://worldchinesemedicineforum.org/

Moving forward, Tianjiang Pharmaceutical will continue to uphold its corporate mission of “Chinese Medicine for a Better Modern Life,” actively fulfilling its responsibility as a central enterprise to support global health needs in a comprehensive and full-cycle manner. The Forum will also keep gathering top experts, scholars, and researchers in the field of TCM, focusing on the distinctive strengths of specialized diseases, sharing cutting-edge research outcomes, and accelerating the international dissemination and high-quality development of TCM, thereby contributing more TCM wisdom and strength to building a global community of health for all.

Disclaimer: This article is reproduced from other media. The purpose of reprinting is to convey more information. It does not mean that this website agrees with its views and is responsible for its authenticity, and does not bear any legal responsibility. All resources on this site are collected on the Internet. The purpose of sharing is for everyone's learning and reference only. If there is copyright or intellectual property infringement, please leave us a message.

Newest

1The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

2The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

3Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

4Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

5Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

6MEXC Claims Dual Wins at BeInCrypto 100 Awards as Best Centralized Exchange and Best Exchange in LATAM

MEXC Claims Dual Wins at BeInCrypto 100 Awards as Best Centralized Exchange and Best Exchange in LATAM

©copyright 2009-2020 Singapore Info Map